搜索结果

   HSD11B2

靶点ID:TCMBANKGE006866

靶点别名:AME; AME1; HSD11K; HSD2; SDR9C3

靶点描述:hydroxysteroid 11-beta dehydrogenase 2

染色体:16

染色体位置:16q22.1

靶点类型:protein-coding

HERB_ID:HBTAR001927

HGNC_Link:5209

OMIM_Link:614232

Ensembl_Link:ENSG00000176387

   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN025270 araban CN(C)C(=S)SSC(=S)N(C)C
TCMBANKIN029162 18beta-glycyrrhetinic acid AJ-72559; Rhetinic Acid; C02283; GLYCYRRHETINIC ACID; 18-beta-Glycyrrhetinic acid; 1449-05-4; Glycyrrhetic acid; Hidermart; CHEMBL230006; SMR000058239; SR-01000721867-5; NCGC00142473-03; 18beta-Glycyrrhetinic acid, purum, >=97.0% (T); UNII-P540XA09DR; Enoxolone (Glycyrrhetin); 107420-91-7; Enoxolone, Glycyrrhetinic acid; CCRIS 3962; LMPR0106150014; 18beta-Glycyrrhetic acid; 4-10-00-03775 (Beilstein Handbook Reference); BB_NC-0599; HMS2233P23; LS-7417; (3?)-3-Hydroxy-11-oxoolean-12-en-30-oic acid; Opera_ID_1048; D0U8IF; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; NSC-35350; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo- (8CI); AC-1925; Glycyrrhetinic acid; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxidanyl-13-oxidanylidene-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; HY-N0180; Arthrodont; Hidermart (TN); DTXSID9020669; SR-01000721867-3; MLS002207101; Enoxolona; Glycyrrhetinic acid (JAN); A-Hydroxy-11-oxoolean-12-en-30-olic acid; SR-01000721867-6; Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3beta,20beta)-; (3beta)-3-hydroxy-11-oxoolean-12-en-30-oic acid; subglycyrrhelinic acid; SCHEMBL18540; 471-53-4; Olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-; BG01168029; FT-0082445; BX-1; Glycyrrhetin; D00156; NCGC00017244-03; 202522-39-2; 18-beta-Glycyrrhetic acid; SR-01000721867-4; Enoxolonum [INN-Latin]; SBB006496; GM-1658; Q-201057; NSC-35347; NSC 35347; (5S,8S,15S,18S,1R,2R,10R,14R,20R)-18-hydroxy-1,2,5,8,15,19,19-heptamethyl-13-o xopentacyclo[12.8.0.0<2,11>.0<5,10>.0<15,20>]docos-11-ene-8-carboxylic acid; alpha-Glycyrrhetinic acid; Tox21_112726; 130100-EP2295411A1; ZINC19203131; Biosone; D08LGJ; Bio-0549; Enoxolone; 18beta-Glycyrrhetinic acid; 3?-Hydroxy-11-oxo-18?,20?-olean-12-en-29-oic acid; Enoxolone (Glycyrrhetinic acid); 50510_FLUKA; BDBM50233538; Uralenic acid; NCGC00017244-04; P540XA09DR; 18beta-glycyrrhetic acid; C30H46O4; Jintan; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo-; CAS-471-53-4; Tox21_200799; SR-01000721867; Enoxolone (INN); MLS001146949; MLS000028748; [(125)I] RB129; G10105_ALDRICH; (3beta,20beta)-3-Hydroxy-11-oxo-olean-12-en-29-oic acid; s2296; CCG-208506; 8055-71-8; EINECS 207-444-6; (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid; Enoxolona [INN-Spanish]; GlycyrrhetinicAcid; 18b-Glycyrrhetic acid; AC1L1UIT; 130100-EP2269977A2; KS-1262; Glycyrrhetinate; Glycyrrhetinic acid [JAN]; (3alpha,5xi,8alpha,9xi,17alpha,18xi)-3-hydroxy-11-oxoolean-12-en-29-oic acid; BC201656; Enoloxone; Enoxolone [INN:BAN:DCF]; 18 beta-glycyrrhetinic acid; 3beta-Hydroxy-11-oxo-18beta,20beta-olean-12-en-29-oic acid; enoxolone; DSSTox_RID_75722; 18 beta-Glycyrrhetintic Acid; DSSTox_CID_669; 3-Glycyrrhetinic acid; 3beta-hydroxy-11-oxoolean-12-en-29-oic acid; NCGC00181115-01; Enoxolone; STX-352; AKOS016036757; 15301-63-0; G0149; MFCD00003706; ST24038257; Enoxolone, European Pharmacopoeia (EP) Reference Standard; ST056310; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-13-keto-2,4a,6a,6b,9,9,12a-heptamethyl-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; AKOS015960428; 471G534; NCGC00258353-01; DB13089; Tox21_110804; CBW; DSSTox_GSID_20669; D0F6IV; MolPort-002-507-130; A827163; (3beta,5beta,14beta)-3-Hydroxy-11-Oxoolean-12-En-29-Oic Acid; 18beta-Glycyrrhetinic acid, 97%; CHEBI:30853; AC-8906; AN-14462; API0002854; BRN 2229654; Glyciram; 18beta-Glycyrrhetinic acid; MCULE-4676598997; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; 3-beta-Hydroxy-11-oxoolean-12-en-30-oic acid; BG00824432; Enoxolone [BAN:DCF:INN]; CS-W020624; S00284; Enoxolonum; 299198-00-8 C30H46O4 470.68 CC1(C2CCC3(C(C2(CCC1O)C)C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C
TCMBANKIN032313 phthalate C8H4O4-2 164.11 g/mol C1=CC=C(C(=C1)C(=O)[O-])C(=O)[O-]
TCMBANKIN036276 cortisone C21H28O5 360.4 g/mol CC12CCC(=O)C=C1CCC3C2C(=O)CC4(C3CCC4(C(=O)CO)O)C
TCMBANKIN036866 glycyrrhizic acid glycyrrhizicacid; CS-W019908; Glycyrrhizic acid C42H62O16 822.93 CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C
TCMBANKIN036867 glycyrrhetinic acid beta-Glycyrrhetic acid; glycyrrhetinicacid; 3-hydroxy-11-oxoolean-12-en-29-oate; (2S,4aS,6aS,6bR,10S,12aS)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; LT00233150; Glycyrrhetic acid; Glycyrrhetinic; 3b-hydroxy-11-oxo-Olean-12-en-30-oic acid; 3-hydroxy-11-oxoolean-12-en-29-oic acid (ACD/Name 4.0); 18b-Glycyrrhetic acid; Glycyrrhetin; Glycyrrhetinate; 3b-Hydroxy-11-oxoolean-12-en-30-oic acid; 18b-Glycyrrhtinic acid; Biosone; 3b-Hydroxy-11-oxoolean-12-en-30-oate; 3-Glycyrrhetinic acid; SCHEMBL13144257; 18b-Glycyrrhetinic acid; NCGC00186652-01; 3b-hydroxy-11-oxo-Olean-12-en-30-oate; b-glycyrrhetic acid; (2S,4AS,6AS,6BR,10S,12AS)-10-HYDROXY-2,4A,6A,6B,9,9,12A-HEPTAMETHYL-13-OXO-3,4,5,6,7,8,8A,10,11,12,12B,14B-DODECAHYDRO-1H-PICENE-2-CARBOXYLIC ACID; a-glycyrrhetinic acid C30H46O4 470.68 CC1(C2CCC3(C(C2(CCC1O)C)C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C
TCMBANKIN037368 glycyrrhetic acid acetate C32H48O5 512.7 g/mol CC(=O)OC1CCC2(C(C1(C)C)CCC3(C2C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C
TCMBANKIN038293 progesterone Cyclogesterin; Luteovis; Progeffik; (8S,9S,10R,13S,14S,17S)-17-ethanoyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Gesterol 50; Corlutin; Syngestrets; NCGC00090798-02; D4-Pregnene-3,20-dione; Hormoluton; Pranone; Crinone progesterone gel; Gesterol 100; Prometrium; Proluton; Luteodyn; Prestwick0_000477; Progestasert; SPBio_002553; .delta.4-Pregnene-3,20-dione; Pregnenedione; NSC-9704; P3972_SIGMA; Methylpregnone; 4-Pregnene-3,20-dione; Prolutone; U 3672; Lutocylin; Colprosterone; Utrogest; Lutocylol; CHEBI:17026; SMR000058345; Corporin; Lipolutin; NCGC00090798-01; P8783_SIGMA; Synovex S; ACon1_002078; 3,20-Pregnene-4; Prestwick_411; Progesterone, water-soluble; Cyclogest; progesterone ; Luteal hormone; Prolets; AIDS070516; NCI60_042166; (S)-Pregn-4-en-3,20-dione; 6.alpha.-Methylpregn-4-en-17.alpha.-ol-3,20-dione; Prolidon; NSC 64377; (8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Nalutron; Progesterone [BAN:INN:JAN]; Progesteronum [INN-Latin]; STR; Flavolutan; Percutacrine Luteinique; Prontogest; Lutocyclin M; Akrolutin; Lugesteron; Corlutina; SCHEMBL12237373; ZINC03814383; Gynlutin; Gynoluton; Prestwick3_000477; Lutogyl; Progesterone: 2-hydroxypropyl-beta-cyclodextrin complex; Crinone (TN); Gynolutone; Spectrum5_002053; Gesterol; AIDS-070516; Progestronol; Luteopur; Corpus luteum hormone; Lutoform; Luteol; 6alpha-Methylpregn-4-en-17alpha-ol-3,20-dione; 17alpha-Progesterone; STOCK1N-52522; Progesterona [INN-Spanish]; Hormoflaveine; Pregn-4-ene-3,20-dione, 17alpha-hydroxy-6alpha-methyl-; Progesterone [Progestins]; Delta(4)-pregnene-3,20-dione; Progesterone: HBC complex; Delta4-Pregnene-3,20-dione; .beta.-Progesterone; Piaponon; Progestrel; Primolut; Gestone; Pregnene-3,20-dione; Syntolutan; NSC64377; MEGxm0_000472; Progesteron; Gelbkoerperhormon; Membrettes; Progestogel; Gestron; EU-0100895; MLS000028517; Prolutin; EINECS 200-350-6; Luteinique; 57-83-0; Progestron; P9776_SIGMA; NCGC00179853-01; Luteol (VAN); Utrogestan; Lutidon; Progesterol; Luteosan; Gestormone; Gestiron; Progesterone; Lutocuclin M; D00066; Endometrin; Lutin; Progestol; Fologenon; C00410; BG01605063; Lucorteum; 8023-13-0; AI3-51682; 8012-32-6; Luteogan; Agolutin; Progesterone (JP15/USP/INN); 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; MLS000758277; Crinone; 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; Luteohormone; S00293; BPBio1_000676; 17.alpha.-Progesterone; Pregn-4-ene-3,20-dione, 17.alpha.-hydroxy-6.alpha.-methyl-; CMC_13406; NSC 9704; NCGC00022185-06; Luteocrin normale; Progestosol; Protormone; (S)-4-Pregnene-3,20-dione; P6149_SIGMA; Luteine; Lutren; P7556_ALDRICH; 257630-50-5; COL-1620; MolPort-001-740-063; SBB012538; delta(sup4)-Pregnene-3,20-dione; NSC9704; component of Cyclogesterin; Syngesterone; FE-999913; Bio-luton; Prestwick1_000477; NCGC00022185-07; nchembio.2007.53-comp14; Pregn-4-ene-3,20-dione; (1S,3BS,9AR,11AS)-1-ACETYL-9A,11A-DIMETHYL-1H,2H,3H,3AH,3BH,4H,5H,8H,9H,9BH,10H,11H-CYCLOPENTA[A]PHENANTHREN-7-ONE; 753497-20-0; CCRIS 533; Vitarrine; delta(sup 4)-Pregnene-3,20-dione; Progestone; Luteum; Lipo-Lutin; Progestin; Lutociclina; Progesteronum; WLN: L E5 B666 OV MUTJ A1 E1 FV1; Progekan; .delta.(sup4)-Pregnene-3,20-dione; 46665_RIEDEL; AKOS030503393; Projestaject; Lingusorbs; Lucorteum Sol; Lopac0_000895; Lutex; P0130_SIGMA; Prochieve; Corluvite; BSPBio_000614; BRD-A51738545-001-01-0; Prestwick2_000477; Luteostab; Progesterone; 4-Pregnene-3,20-dione; Lutocyclin; Glanducorpin; Prometrium (TN); HSDB 3389; Lutromone; (S)-Progesterone C21H30O2 314.46 CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
TCMBANKIN058990 forskolin coleonol C22H34O7 410.5 g/mol CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O
TCMBANKIN059541 glycyrrhizin C42H62O16 822.93 CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C
TCMBANKIN061207 Di-n-butyl phthalate C16H22O4 278.34 g/mol CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC
   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI002512 Digestive System Diseases Abnormality of the digestive system; Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI007313 Pathological Conditions, Signs and Symptoms; Musculoskeletal Diseases - Disease or Syndrome phenotype
TCMBANKDI007520 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI007737 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process disease
TCMBANKDI009231 Pathological Conditions, Signs and Symptoms; Infections Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI009278 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI009686 Nervous System Diseases; Endocrine System Diseases - Disease or Syndrome disease
TCMBANKDI009951 Nutritional and Metabolic Diseases; Musculoskeletal Diseases Abnormality of the skeletal system Disease or Syndrome disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI012074 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of prenatal development or birth; Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI012126 Eye Diseases; Cardiovascular Diseases Abnormality of the eye; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI014839 Nutritional and Metabolic Diseases; Immune System Diseases; Endocrine System Diseases - Disease or Syndrome disease
TCMBANKDI015256 Chemically-Induced Disorders; Mental Disorders - Mental or Behavioral Dysfunction phenotype
TCMBANKDI015485 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI016946 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases - Disease or Syndrome disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI017425 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI019825 Neoplasms - Neoplastic Process disease
TCMBANKDI020603 Pathological Conditions, Signs and Symptoms - Anatomical Abnormality phenotype
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI028664 - - Finding phenotype
TCMBANKDI029220 Nutritional and Metabolic Diseases; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI029791 Nutritional and Metabolic Diseases - Disease or Syndrome phenotype
TCMBANKDI030416 Infections - Disease or Syndrome disease
TCMBANKDI030851 Immune System Diseases; Endocrine System Diseases Abnormality of the endocrine system Finding phenotype
TCMBANKDI031192 Neoplasms; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI032321 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases - Disease or Syndrome disease

Home | Browse | Search | Predict | Data | Contact | Help

Copyright © KUST | 滇IICP备16009434号-1 | Dai SX Lab